Vinva Investment Management Ltd Raises Position in CVS Health Corporation $CVS

Vinva Investment Management Ltd boosted its position in CVS Health Corporation (NYSE:CVS) by 22.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 105,486 shares of the pharmacy operator’s stock after purchasing an additional 19,432 shares during the period. Vinva Investment Management Ltd’s holdings in CVS Health were worth $7,972,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Riggs Asset Managment Co. Inc. increased its holdings in CVS Health by 21,285.0% in the 3rd quarter. Riggs Asset Managment Co. Inc. now owns 4,277 shares of the pharmacy operator’s stock worth $322,000 after acquiring an additional 4,257 shares during the last quarter. Natixis Advisors LLC lifted its holdings in CVS Health by 7.4% during the third quarter. Natixis Advisors LLC now owns 1,333,737 shares of the pharmacy operator’s stock valued at $100,550,000 after purchasing an additional 92,377 shares during the last quarter. Ameriflex Group Inc. lifted its holdings in CVS Health by 361.2% during the third quarter. Ameriflex Group Inc. now owns 2,624 shares of the pharmacy operator’s stock valued at $198,000 after purchasing an additional 2,055 shares during the last quarter. Blair William & Co. IL boosted its position in CVS Health by 2.2% during the third quarter. Blair William & Co. IL now owns 63,409 shares of the pharmacy operator’s stock worth $4,780,000 after purchasing an additional 1,357 shares during the period. Finally, Modern Wealth Management LLC boosted its position in CVS Health by 12.9% during the third quarter. Modern Wealth Management LLC now owns 3,961 shares of the pharmacy operator’s stock worth $299,000 after purchasing an additional 452 shares during the period. 80.66% of the stock is owned by institutional investors.

CVS Health Stock Performance

NYSE CVS opened at $77.91 on Monday. The company’s 50 day simple moving average is $78.49 and its two-hundred day simple moving average is $77.65. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.84 and a quick ratio of 0.63. CVS Health Corporation has a 1 year low of $58.35 and a 1 year high of $85.15. The stock has a market capitalization of $99.12 billion, a PE ratio of 56.46, a P/E/G ratio of 0.81 and a beta of 0.49.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Tuesday, February 10th. The pharmacy operator reported $1.09 EPS for the quarter, beating analysts’ consensus estimates of $1.00 by $0.09. CVS Health had a net margin of 0.44% and a return on equity of 11.31%. The firm had revenue of $105.69 billion during the quarter, compared to analyst estimates of $103.67 billion. During the same period in the previous year, the business earned $1.19 EPS. The business’s revenue for the quarter was up 8.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 5.940-6.140 EPS. Analysts predict that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Shareholders of record on Thursday, January 22nd were paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date was Thursday, January 22nd. CVS Health’s dividend payout ratio is currently 192.75%.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS launched Health100, a new AI-native health‑tech subsidiary and consumer engagement platform built with Google Cloud. Management says the platform will unify data across payers, providers and pharmacies to drive personalized engagement and better outcomes — a potential long‑term revenue and margin lever if adoption scales. CVS taps Google Cloud to roll out AI-powered health platform
• Positive Sentiment: Broad media and trade coverage highlights the Google Cloud tie‑up and Health100 rollout, increasing visibility for CVS as a tech-enabled healthcare integrator — this can support multiple revenue streams (retail, PBM, value-based care) over time. CVS Health And Google Launch AI Business To ‘Personalize Healthcare’
• Positive Sentiment: Analyst and long‑term bulls point to margin recovery and FY2026 guidance (CVS set EPS guidance ~5.94–6.14) plus a recent quarterly beat — supporting the thesis that Medicare Advantage margin improvement and Health100 monetization could drive sizable upside over 12–24 months. CVS Health: Stop Catastrophizing, Start Believing – Here’s Why
• Neutral Sentiment: Market commentary questions whether recent gains already price in recovery — some pieces analyze valuation and one‑year returns, useful for timing but not a direct catalyst. Is CVS Health (CVS) Still Attractive After A 27% One Year Share Price Gain
• Negative Sentiment: Regulatory risk in Tennessee: a proposed bill would bar companies from owning both retail pharmacies and PBMs, and CVS warned it could close all 134 locations in the state if the law passes — an example of state‑level regulatory risks that could hit revenue, footprint and investor sentiment. CVS warns bill would force shutdown of 134 pharmacies in this state
• Negative Sentiment: Wolfe Research trimmed its price target on CVS, a modest negative for near‑term sentiment even though the firm remains focused on longer‑term fundamentals. Wolfe Research Cuts CVS Health (NYSE:CVS) Price Target to $97.00

Wall Street Analyst Weigh In

Several research firms have recently issued reports on CVS. TD Cowen boosted their price target on shares of CVS Health from $100.00 to $105.00 and gave the company a “buy” rating in a research report on Wednesday, December 10th. Robert W. Baird lifted their price objective on shares of CVS Health from $82.00 to $92.00 and gave the company an “outperform” rating in a research note on Wednesday, December 10th. Argus lowered their target price on shares of CVS Health from $91.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, January 28th. Wolfe Research cut their price target on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Finally, Wells Fargo & Company reduced their price target on CVS Health from $103.00 to $102.00 and set an “overweight” rating for the company in a research report on Thursday, November 13th. Nineteen research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $94.91.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.